The comparision of sertaconazole versus pimecrolimus in the treatment of facial seborrheic dermatitis
Not Applicable
- Conditions
- Seborrheic dermatitis (SD).Seborrhoeic dermatitis
- Registration Number
- IRCT2014041613853N1
- Lead Sponsor
- Vice-chancellor for research -Semnan University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
inclusion criteria: facial seborrheic dermatitis; any systemic disease.
exclusion criteria: taking drugs such as methyldopa, chlorpromazine, cimetidine; use of local and systemic anti-acne ,steroid and immune modulators drugs one month before; lactation and pregnancy.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvment. Timepoint: 2 and 4 weeksafter starting treatment. Method of measurement: dermatologist examination.;Exacerbation. Timepoint: 1 month after stoping treatment. Method of measurement: dermatologist examination.;Treatment duration. Timepoint: 4 weeks. Method of measurement: time.;Patient satisfaction. Timepoint: 2 and 4 weeks after starting treatment. Method of measurement: question of patient.
- Secondary Outcome Measures
Name Time Method Side effect. Timepoint: 2 and 4 weeks after starting treatment. Method of measurement: dermatologist examination.